Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity and Emerging Strategies
Genes · 2026
DOI: 10.3390/genes17010056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2026. Verfasst von Maria Chrysostomaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Precision Medicine, Polyneuropathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hereditary polyneuropathies represent a genetically and clinically heterogeneous group of disorders affecting the peripheral nervous system, characterized by progressive motor, sensory, and autonomic impairment. Advances in molecular genetics have identified key causative genes, including PMP22, MPZ, MFN2, TTR, EGR2, and CX32 (GJB1), which are implicated in Charcot–Marie–Tooth disease, Dejerine–Sottas syndrome, and related neuropathies. These conditions display substantial allelic and locus heterogeneity. Pathogenetically, mechanisms involve impaired myelin maintenance, disrupted axonal transport, mitochondrial dysfunction, and aberrant Schwann cell biology. Despite these insights, therapeutic options remain limited, and there is a pressing need to translate genetic findings into effective interventions. This review aims to provide a comprehensive synthesis of current knowledge compiling all known mutations resulting in hereditary polyneuropathies. In addition, it underscores the molecular pathomechanisms of hereditary polyneuropathies and evaluates emerging therapeutic strategies, including adeno-associated virus mediated RNA interference, CRISPR-based gene editing, antisense oligonucleotide therapy, and small-molecule modulators of axonal degeneration. Furthermore, the integration of precision diagnostics, such as next-generation sequencing and functional genomic approaches, is discussed in the context of personalized disease management. Collectively, this review underscores the need for patient-centered approaches in advancing care for individuals with hereditary polyneuropathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Maria Chrysostomaki, Despoina Chatzi, Stella Aikaterini Kyriakoudi, Soultana Meditskou, Maria Eleni Manthou, Sofia Gargani, Paschalis Theotokis, Iasonas Dermitzakis
Zitieren
APA
Chrysostomaki, M., Chatzi, D., Kyriakoudi, S. A., Meditskou, S., Manthou, M. E., Gargani, S., Theotokis, P., & Dermitzakis, I. (2026). Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity and Emerging Strategies. Genes. https://doi.org/10.3390/genes17010056
Vancouver
Chrysostomaki M, Chatzi D, Kyriakoudi SA, Meditskou S, Manthou ME, Gargani S, et al. Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity and Emerging Strategies. Genes. 2026. doi:10.3390/genes17010056
BibTeX
@article{Chrysostomaki2026,
author = {Chrysostomaki, Maria and Chatzi, Despoina and Kyriakoudi, Stella Aikaterini and Meditskou, Soultana and Manthou, Maria Eleni and Gargani, Sofia and Theotokis, Paschalis and Dermitzakis, Iasonas},
title = {Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity and Emerging Strategies},
journal = {Genes},
year = {2026},
doi = {10.3390/genes17010056}
}
EUVIMED